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from Varian (Varian, Palo Alto, USA) integrates, for cranial 
lesions, the common Cone Beam Computed Tomography 
(CBCT) and kV-MV portal images to the Optical Surface 
Monitoring System (OSMS), a device able to detect real-time 
patient’s face movements in all 6 couch axes (vertical, 
longitudinal, lateral, rotation, pitch and roll). We have 
evaluated the OSMS imaging capability in checking the 
patient’s position and monitoring its motion. 
Materials and Methods: An home-made cranial phantom was 
developed to evaluate the OSMS accuracy in four different 
experiments: (i) comparison with CBCT in isocenter location; 
(ii) capability to recognize predefined shifts up to 2-3°/cm; 
(iii) evaluation at different couch angles; (iv) ability to 
properly reconstruct the surface when one camera is covered 
by the EDGE. 
Results: The OSMS system showed to be accurate for patient 
positioning respect to the CBCT imaging system with 
difference of 0.6±0.3 mm for linear vector displacement, 
with a maximum rotational inaccuracy of 0.3°. OSMS 
presented an accuracy of 0.3 mm for displacement up to 1 
cm and 1°, and 0.5 mm for larger displacements. Different 
couch angles induced a mean vector uncertainty <0.4 mm. 
Coverage of one camera produced an uncertainty <0.5 mm. 
Conclusions: In conclusion, OSMS could be considered 
suitable for SRS accuracy positioning and monitoring. 
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Purpose/Objective: The radiobiological characteristics of 
prostate cancer have been investigated and evidence 
suggests a low alpha/beta ratio. As a result, increased 
tumour cell kill should correlate with increased dose per 
fraction. Improved tumour control rates should be possible by 
delivering large doses/fraction without increasing normal 
tissue toxicity.  
Although in-vivo studies have supported this, the radiation 
delivery techniques reported have tended to use Cyberknife 
or other less sophisticated linear accelerator techniques.  
The objective of this study was to assess feasibility, safety 
and efficiency of delivering FFF volumetric arc therapy for 
prostate SABR using: fiducial markers for verification and 
MRI/CT fusion for delineation. 
Materials and Methods: Ethically approved safety and 
feasibility study including first 17 patients with low-
intermediate risk prostate cancer, PSA ≤ 20 ng/ml and a 
Gleason score ≤7. MRI/CT image fusion was used for target 
delineation. 
Patients planned using Varian Eclipse (v.10.0.42) 10X FFF (2 
arcs) and treated using Varian Truebeam STX to a dose of 
35Gy/5 fractions. Patients were treated on the planned 
delivery schedule of alternate days which resulted in an 
overall treatment period of 11 days. Cone-beam CT images 
were acquired pre and post treatment. Patients were 
assessed for acute and late gastro-intestinal (GI) and genito-
urinary (GU) toxicity before each treatment and at 4, 10 and 
18 weeks. Planning criteria was assessed ensuring it was a 
clinically feasible method of planning and beam on time was 
recorded to assess efficiency. 
Results:  
Feasibility: Clinically acceptable plans were achieved for 
100% of reported patients. (Table 1) 
Safety: No RTOG acute toxicity of grade > 3 was recorded for 
any of the 17 patients. 
Efficiency: Mean treatment time for a course of conventional 
radiotherapy 1814.48 seconds and for SABR 603.1 seconds. 
This demonstrates a significant reduction in BOT of 67% for 
study patients (p=<0.001). (Table 1) 
 
Conclusions: Following the assessment of the first 17 
patients, the research team is satisfied that all outcomes 
from this study are being met. Planning data has been 
achieved for all patients allowing treatment using the study 
method to proceed. Treatment has been tolerated well by 
patients with acute toxicity being within acceptable limits. A 
significant reduction in BOT has also demonstrated the study 
technique to be efficient.  
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Purpose/Objective: An important step in radiotherapy 
treatment delivery is the accuracy of patient positioning. In 
order to ensure the accuracy, stability and reproducibility of 
the HexaPODTM robotic table, we started doing, since its 
initial clinical use in March 2014, weekly setup verifications 
with a QUASARTM Penta-Guide phantom in combination with 
Elekta XVI CBCT. The objective is to verify if the couch, after 
applying known shifts in all directions, is able to reposition 
the phantom at the isocentre with high precision and very 
low and small deviations. Quality assurance (QA) of the XVI 
system alone is performed apart. 
